

IN THE CLAIMS

1-4. (Cancelled)

5. (Currently Amended) A method for ~~treating or preventing a brain disorder~~
diminishing a cerebral vasospasm associated with a subarachnoid hemorrhage
comprising administering to a subject in need thereof an effective amount of ~~an NF-~~
 ~~κ B decoy~~ a composition comprising:

an oligonucleotide or modified oligonucleotide comprising the base sequence
of SEQ ID NO: 1 and

a liposomal delivery system

~~which inhibits the activation of at least one gene by the NF- κ B transcription~~
~~factor, to a subject in need thereof, wherein said oligonucleotide or modified~~
oligonucleotide is double-stranded.

6. (Currently Amended) The method of Claim 5, wherein said composition is
administered intracisternally ~~brain disorder is associated with encephalopathy.~~

7. (Cancelled)

8. (Currently Amended) The method of Claim 5, wherein said liposomal
delivery system is a cationic liposomal delivery system ~~said brain disorder is cerebral~~
~~vasospasm associated with subarachnoid hemorrhage.~~

9. (Currently Amended) The method of Claim 5, wherein said liposome
delivery system comprises a membrane fusion promoter ~~NF- κ B decoy is a nucleic~~
~~acid or an analog thereof that antagonizes the binding of nucleic acids to NF- κ B.~~

10. (Cancelled)

11. (Cancelled)

12. (Currently Amended) The method of Claim 5, wherein said ~~NF- κ B decoy~~
oligonucleotide or modified oligonucleotide comprising the base sequence of SEQ ID

NO: 1 is a cyclic ~~nucleic acid or nucleic acid~~ oligonucleotide or modified oligonucleotide analog.

13. (Currently Amended) The method of Claim 5, wherein said ~~NF- κ B decoy~~ composition comprises an oligonucleotide comprising the base sequence of SEQ ID NO: 1 which is DNA.

14. (Currently Amended) The method of Claim 5, wherein said ~~NF- κ B decoy~~ is composition comprises a modified oligonucleotide comprising the base sequence of SEQ ID NO: 1 or a pseudonucleotide.

15. (Currently Amended) The method of Claim 5, wherein said ~~NF- κ B decoy~~ is composition comprises an S-oligonucleotide, an oligonucleotide in which one or more methyl phosphate group(s) carrying no charge has (have) been substituted for the phosphodiester bond, an acylated oligonucleotide, or an alkylated oligonucleotide, comprising the base sequence of SEQ ID NO: 1.

16. (Currently Amended) The method of Claim 5, wherein said ~~NF- κ B decoy~~ oligonucleotide or modified oligonucleotide comprises ~~multiple~~ more than one units of a ~~nucleotide or nucleotide analog~~ the base sequence of SEQ ID NO: 1.

17. (Currently Amended) The method of Claim 5, wherein said ~~NF- κ B decoy~~ oligonucleotide or modified oligonucleotide comprises an individual unit of the base sequence of SEQ ID NO: 1.

18. (Currently Amended) A liposome comprising ~~an NF- κ B decoy~~ oligonucleotide or modified oligonucleotide comprising the base sequence of SEQ ID NO: 1, ~~which inhibits the activation of at least one gene by the NF- κ B transcription factor,~~ wherein said oligonucleotide or modified oligonucleotide is double-stranded.

19. (Previously Presented) The liposome of Claim 18 that comprises a cationic lipid.

20. (Previously Presented) The liposome of Claim 18 that comprises a membrane-fusion promoter.
21. (Previously Presented) The liposome of Claim 18 that comprises a large unilamellar vesicle (LUV) structure.
22. (Previously Presented) The liposome of Claim 18 that comprises a multilamellar vesicle (MLV) structure.
23. (Previously Presented) The liposome of Claim 18 that comprises a small unilamellar vesicle (SUV) structure.
24. (Cancelled)